8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jul 29, 2013)

Filed July 29, 2013For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on July 29, 2013, to report its financial results for the quarter ended June 30, 2013. The primary purpose of this filing is to furnish the market with the company's earnings press release, which provides a detailed overview of its operational and financial performance during the second quarter of 2013. Investors should refer to the attached press release (Exhibit 99.1) for specific financial figures, including revenue, net income, and earnings per share, as well as commentary on business developments and outlook. While the 8-K itself is brief and primarily serves as a cover for the press release, the attached document is crucial for understanding Vertex's performance. Investors will want to pay close attention to any updates on key pipeline drugs, commercial product sales, and any guidance provided for future quarters or the full fiscal year. The filing indicates that the press release information is not deemed "filed" for Section 18 purposes, meaning it does not carry the same legal liability as traditional SEC filings, but it remains the primary source of information for investors regarding the quarter's results.

Key Highlights

  • 1Vertex Pharmaceuticals Inc. (VRTX) announced its Q2 2013 financial results via an 8-K filing on July 29, 2013.
  • 2The 8-K filing incorporates by reference the company's earnings press release dated July 29, 2013.
  • 3Investors are directed to Exhibit 99.1 (the press release) for detailed financial results and operational updates for the quarter ended June 30, 2013.
  • 4The filing confirms the reporting of consolidated financial results for the second quarter of 2013.
  • 5Information in the press release is furnished, not filed, under Section 18 of the Exchange Act, limiting liability but remaining a key source for performance data.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Vertex Pharmaceuticals' consolidated financial results for the quarter ended June 30, 2013, by attaching its earnings press release.

The detailed financial results and operational commentary are provided in the press release dated July 29, 2013, which is attached as Exhibit 99.1 to this 8-K filing.

No, the information set forth in the press release is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated into other SEC filings. However, it remains the official source of the company's reported results for the period.

Investors should look for key metrics such as revenue, net income, earnings per share (EPS), cash flow, and any updates on the company's financial guidance for the remainder of the year. Additionally, information regarding the performance of Vertex's key drugs and pipeline progress would be highly relevant.